SeraGene Therapeutics announces the publication of extensive preclinical proof-of-concept data for its lead asset for bleeding disorders, SG-100, in Science Translational Medicine.
SeraGene is pleased to announce the latest data on SG-100, a siRNA therapy being developed as a treatment to prevent or decrease bleeding in patients with bleeding disorders.
SG-100 stabilizes formed clots by preventing their premature degradation, as demonstrated by decrease in spontaneous bleeding and bleeding after injury in mouse and canine models of hemophilia A. This work also demonstrated the favourable safety and tolerability profile of this MoA in mouse and canine when used as a prophylactic repeat-dosing regimen for over 4 months.
